Cargando…

Disease-modifying drugs in Alzheimer’s disease

Alzheimer’s disease (AD) is an age-dependent neurodegenerative disorder and the most common cause of dementia. The early stages of AD are characterized by short-term memory loss. Once the disease progresses, patients experience difficulties in sense of direction, oral communication, calculation, abi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghezzi, Laura, Scarpini, Elio, Galimberti, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862506/ https://www.ncbi.nlm.nih.gov/pubmed/24353405 http://dx.doi.org/10.2147/DDDT.S41431

Ejemplares similares

Role of Genetics and Epigenetics in the Pathogenesis of Alzheimer’s Disease and Frontotemporal Dementia(1)
por: Fenoglio, Chiara, et al.
Publicado: (2018)

The Role of the Innate Immune System in Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Eye on Microglia
por: Ridolfi, Elisa, et al.
Publicado: (2013)

Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery
por: Buccellato, Francesca Romana, et al.
Publicado: (2021)

Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
por: Buccellato, Francesca R., et al.
Publicado: (2023)

Lack of Association between the GPR3 Gene and the Risk for Alzheimer's Disease
por: Dominici, Roberto, et al.
Publicado: (2011)

Genetics of Frontotemporal Lobar Degeneration
por: Galimberti, Daniela, et al.
Publicado: (2012)

Weight Loss Predicts Progression of Mild Cognitive Impairment to Alzheimer’s Disease
por: Cova, Ilaria, et al.
Publicado: (2016)

An Emerging Role for Long Non-Coding RNA Dysregulation in Neurological Disorders
por: Fenoglio, Chiara, et al.
Publicado: (2013)

MicroRNAs as Active Players in the Pathogenesis of Multiple Sclerosis
por: Fenoglio, Chiara, et al.
Publicado: (2012)

TREM2 Expression and Amyloid-Beta Phagocytosis in Alzheimer’s Disease
por: La Rosa, Francesca, et al.
Publicado: (2023)

IL-33 and its decoy sST2 in patients with Alzheimer’s disease and mild cognitive impairment
por: Saresella, Marina, et al.
Publicado: (2020)

Epigenetic Regulation of Fatty Acid Amide Hydrolase in Alzheimer Disease
por: D'Addario, Claudio, et al.
Publicado: (2012)

CSF pro-orexin and amyloid-β38 expression in Alzheimer's disease and frontotemporal dementia
por: Heywood, Wendy E., et al.
Publicado: (2018)

Pharmacological and Epigenetic Regulators of NLRP3 Inflammasome Activation in Alzheimer’s Disease
por: La Rosa, Francesca, et al.
Publicado: (2021)

Transcranial Direct Current Stimulation Modulates Cortical Neuronal Activity in Alzheimer's Disease
por: Marceglia, Sara, et al.
Publicado: (2016)

A Novel Study and Meta-Analysis of the Genetic Variation of the Serotonin Transporter Promoter in the Italian Population Do Not Support a Large Effect on Alzheimer's Disease Risk
por: Polito, Letizia, et al.
Publicado: (2011)

Altered Extracellular Vesicle miRNA Profile in Prodromal Alzheimer’s Disease
por: Visconte, Caterina, et al.
Publicado: (2023)

Disease-specific plasma levels of mitokines FGF21, GDF15, and Humanin in type II diabetes and Alzheimer’s disease in comparison with healthy aging
por: Conte, Maria, et al.
Publicado: (2020)

The Gut Microbiome–Brain Crosstalk in Neurodegenerative Diseases
por: Ghezzi, Laura, et al.
Publicado: (2022)

Exosome Determinants of Physiological Aging and Age-Related Neurodegenerative Diseases
por: D’Anca, Marianna, et al.
Publicado: (2019)

Extracellular Vesicles in Multiple Sclerosis: Role in the Pathogenesis and Potential Usefulness as Biomarkers and Therapeutic Tools
por: D’Anca, Marianna, et al.
Publicado: (2021)

The Enigmatic Role of Viruses in Multiple Sclerosis: Molecular Mimicry or Disturbed Immune Surveillance?
por: Geginat, Jens, et al.
Publicado: (2017)

Parieto-occipital sulcus widening differentiates posterior cortical atrophy from typical Alzheimer disease
por: Fumagalli, Giorgio G., et al.
Publicado: (2020)

Modulation of MAPK- and PI3/AKT-Dependent Autophagy Signaling by Stavudine (D4T) in PBMC of Alzheimer’s Disease Patients
por: La Rosa, Francesca, et al.
Publicado: (2022)

MiRNA Profiling in Plasma Neural-Derived Small Extracellular Vesicles from Patients with Alzheimer’s Disease
por: Serpente, Maria, et al.
Publicado: (2020)

Profiling of Ubiquitination Pathway Genes in Peripheral Cells from Patients with Frontotemporal Dementia due to C9ORF72 and GRN Mutations
por: Serpente, Maria, et al.
Publicado: (2015)

The Role of Glymphatic System in Alzheimer’s and Parkinson’s Disease Pathogenesis
por: Buccellato, Francesca R., et al.
Publicado: (2022)

Usefulness of Multi-Parametric MRI for the Investigation of Posterior Cortical Atrophy
por: Arighi, Andrea, et al.
Publicado: (2015)

A Novel Automated Chemiluminescence Method for Detecting Cerebrospinal Fluid Amyloid-Beta 1-42 and 1-40, Total Tau and Phosphorylated-Tau: Implications for Improving Diagnostic Performance in Alzheimer’s Disease
por: Arcaro, Marina, et al.
Publicado: (2022)

Alterations of the miR-126-3p/POU2AF1/Spi-B Axis and JCPyV Reactivation in Multiple Sclerosis Patients Receiving Natalizumab
por: Mancuso, Roberta, et al.
Publicado: (2022)

Role of Chitinase 3–like 1 as a Biomarker in Multiple Sclerosis: A Systematic Review and Meta-analysis
por: Floro, Stefano, et al.
Publicado: (2022)

Huperzine A: Is it an Effective Disease-Modifying Drug for Alzheimer’s Disease?
por: Qian, Zhong Ming, et al.
Publicado: (2014)

Disease-modifying drugs for Alzheimer disease: implications for people in Canada
por: Watt, Jennifer A., et al.
Publicado: (2023)

Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson's and Alzheimer's Diseases as Disease Modifying Agents
por: Youdim, Moussa B. H.
Publicado: (2010)

The past, present, and future of disease-modifying therapies for Alzheimer’s disease
por: SUZUKI, Kazushi, et al.
Publicado: (2017)

Mitochondrial Drugs for Alzheimer Disease
por: Bonda, David J., et al.
Publicado: (2009)

Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes
por: Carandini, Tiziana, et al.
Publicado: (2019)

Biomarkers and phenotypic expression in Alzheimer’s disease: exploring the contribution of frailty in the Alzheimer’s Disease Neuroimaging Initiative
por: Canevelli, Marco, et al.
Publicado: (2020)

Facing the digital divide into a dementia clinic during COVID-19 pandemic: caregiver age matters
por: Arighi, Andrea, et al.
Publicado: (2021)

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
por: Golde, Todd E.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mfrq9mm8eg9kjfeeist5su0a6q